Invasive fungal infections are an important cause of morbidity and mortality, especially in
critically ill patients. Increasing resistance rates and inadequate antifungal exposure have …

Purpose: Reduced exposure to echinocandins has been reported in specific patient
populations, such as critically ill patients; however, fixed dosing strategies are still used. The …

Objectives: Our ex vivo study was designed to determine the sequestration of teicoplanin,
tigecycline, micafungin, meropenem, polymyxin B, caspofungin, cefoperazone sulbactam …

Abstract Background and Objective The risk of thrombotic complications in critical patients
with COVID-19 remains extremely high, and multicenter trials failed to prove a survival …

Vulvovaginal candidiasis (VVC) poses a significant problem worldwide affecting women
from all strata of society. It is manifested as changes in vaginal discharge, irritation, itching …

This study aimed to describe the population pharmacokinetics of caspofungin in critically ill
patients receiving extracorporeal membrane oxygenation (ECMO) and to identify dosing …

Objectives Critically ill patients frequently require continuous renal replacement therapy.
Echinocandins are recommended as first-line treatment of candidemia. Preliminary results …

Aim Oral candidiasis is often challenging due to limited effectiveness of topical treatments.
This study aimed to develop novel caspofungin formulations for administration onto the oral …

Objective To describe whether contemporary dosing of antifungal drugs achieves
therapeutic exposures in critically ill patients that are associated with optimal outcomes …

The weaker diffusion of echinocandins in the peritoneal fluid (PF) could promote Candida-
resistant isolates. The aim of this study was to analyze the pharmacokinetics (PK) …